Cabometyx (cabozantinib)

pill
100 % legal and regulated
Secured logistics globally
24/7 track & trace delivery
Safe payment by bank transfer or credit card
5/5
Patients and doctors who have ordered medicines from us have given us a 5 out of 5 star rating for our service

Enquire now
or read
We are registered as an independent intermediary for medicines with the Dutch Ministry of Health

Cabometyx (cabozantinib)

How to buy Cabometyx: You can order Cabometyx (cabozantinib) via TheSocialMedwork if the drug has not been approved and/or is not available in the patient's country. TheSocialMedwork - helping patients and doctors access the latest approved medicines and at the lowest price possible worldwide.

Manufacturer Ipsen Pharma
Disease Kidney Cancer
Indication Renal cell carcinoma
Mode of Action Tyrosine kinase inhibitor
Approval Status EMA approved (EU); FDA approved (USA)
CAS Number 853426-35-4
HS Code 30021098
Strength 20 mg, 40 mg, 60 mg

Who is cabozantinib for?

Cabometyx (cabozantinib) is indicated for the treatment of patients with advanced renal cell carcinoma (a type of kidney cancer) who have received prior anti-angiogenic therapy [1][2].

Recommended dose

Complete information about Cabometyx (cabozantinib) dosage and administration can be found here  [1][2].
The standard dosage is:
  • 60 mg orally, once daily
  • Patients should not eat for at least 2 hours before and at least 1 hour after assumption
  • Cabozantinib tablets should not be substituted with cabozantinib capsules.  
Consult your treating doctor for personalised dosing.

What is cabozantinib and how does it work?

Cabometyx (cabozantinib) is a cancer medicine used to treat adults with advanced renal cell carcinoma (a type of kidney cancer) who have received prior anti-angiogenic therapy [1][2]. The active substance in Cabometyx, cabozantinib, is a ‘tyrosine kinase inhibitor’. This means that it blocks the activity of enzymes known as tyrosine kinases. These enzymes can be found in cancer cells, where they activate several processes including cell division and the growth of new blood vessels to supply the cancer. By blocking the activity of these enzymes in cancer cells, Cabometyx (cabozantinib) reduces the growth and spread of the cancer [3].

What is cabozantinib's approval status?


Cabometyx (cabozantinib) was approved by:
  • FDA (USA) on April 25, 2016 [4]
  • EMA (EU) on  September 9, 2016 [3]
for advanced renal cell carcinoma previously treated with an anti-angiogenic therapy. The approvals were based on a study involving 658 adults with advanced renal cell carcinoma that had got worse despite treatment with an anti-angiogenic therapy. In the study, Cabometyx (cabozantinib) was compared with the cancer medicine everolimus. Results showed a progression-free survival (time patients lived without their disease getting worse) of 7.4 months on average compared with 3.8 months in patients treated with everolimus. Preliminary results indicated that patients treated with Cabometyx (cabozantinib) lived overall longer than patients treated with everolimus (an average of 21.4 months compared with 16.5 months) [3].
References
[1] Summary of Product Characteristics [EMA]: Cabometyx (cabozantinib), Ipsen Pharma, Oct. 2016.
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004163/WC500214071.pdf
[2] Summary of Product Characteristics [FDA]: Cabometyx (cabozantinib), Exelixis Inc., Apr. 2016.
http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208692s000lbl.pdf
[3] EMA. Human Medicines: Cabometyx (cabozantinib), 12/10/2016 (last update: 12/10/2016), cited on 19/01/2017.
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004163/human_med_002018.jsp&mid=WC0b01ac058001d124
[4] Drugs.com. Cabometyx (cabozantinib), 05/07/2016, (last update: 01/06/2017), cited on 19/01/2017.
https://www.drugs.com/mtm/cabometyx.html








"TheSocialMedwork helped us to get the medicine, which was not accessible for us, in the shortest possible time."

- Haoyu, China.
Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM



Share our website

Follow us


DISCLAIMER: The Services of TheSocialMedwork do not replace a physician-patient relationship and are not intended as medical advice. TheSocialMedwork provides patients and physicians with existing treatment options abroad and creates access to these options after the patient and physician have made a professional decision. Privacy Policy / Terms and Conditions
Our service uses cookies.